Kymera Therapeutics, Inc. KYMR has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.
The KT-333 clinical trial includes patients with relapsed/refractory liquid and solid tumors, including T cell lymphomas and leukemia.
Kymera is enrolling patients in the KT-413 clinical study for relapsed/refractory B cell lymphomas, including MYD88-mutant diffuse large B cell lymphoma (DLBCL).
Nello Mainolfi, PhD, Co-Founder, President and CEO, stated, ”These programs demonstrate the potential for targeted protein degradation to target critical nodes that traditional modalities can't effectively address, offering a precision medicine approach to challenging cancers.”
The company anticipates initial safety and proof-of-mechanism clinical data for both programs to in second half of 2022.
Kymera Therapeutics closed Tuesday trading at $14.46.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
